Abstract:Introduction: Glucose and lipid metabolism disturbances has become the third major disease after cancer and cardio-cerebrovascular diseases. Emerging evidence shows that berberine can effectively intervene glucose and lipid metabolism disturbances, but the underlying mechanisms of this remain unclear. To investigate this issue, we performed metagenomic and metabolomic analysis in a group of normal mice (the NC group), mice with disturbances in glucose and lipid metabolism (the MC group) and mice with disturbances in glucose and lipid metabolism after berberine intervention (the BER group). Result: Firstly, analysis of the clinical indicators revealed that berberine significantly improved the blood glucose and blood lipid of the host. The fasting blood glucose level decreased by approximately 30% in the BER group after 8 weeks and the oral glucose tolerance test showed that the blood glucose level of the BER group was lower than that of the MC group at any time. Besides, berberine significantly reduced body weight, total plasma cholesterol and triglyceride. Secondly, compared to the NC group, we found dramatically decreased microbial richness and diversity in the MC group and BER group. Thirdly, LDA effect size suggested that berberine significantly altered the overall gut microbiota structure and enriched many bacteria, including Akkermansia ( p < 0.01), Eubacterium ( p < 0.01) and Ruminococcus ( p < 0.01). Fourthly, the metabolomic analysis suggested that there were significant differences in the metabolomics signature of each group. For example, isoleucine ( p < 0.01), phenylalanine ( p < 0.05), and arbutin ( p < 0.05) significantly increased in the MC group, and berberine intervention significantly reduced them. The arbutin content in the BER group was even lower than that in the NC group. Fifthly, by combined analysis of metagenomics and metabolomics, we observed that there were significantly negative correlations between the reduced faecal metabolites (e.g., arbutin) in the BER group and the enriched gut microbiota (e.g., Eubacterium and Ruminococcus ) ( p < 0.05) Finally, the correlation analysis between gut microbiota and clinical indices indicated that the bacteria (e.g., Eubacterium ) enriched in the BER group were negatively associated with the above-mentioned clinical indices ( p < 0.05). Conclusion: Overall, our results describe that the changes of gut microbiota and metabolites are associated with berberine improving glucose and lipid metabolism disturbances.

Functional Study of the Upregulation of Mirna-27A and Mirna-27B in 3T3-L1 Cells in Response to Berberine.

Mir-10B-5p Regulates 3T3-L1 Cells Differentiation by Targeting Apol6.

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells

[Effects of Berberine on Cell Proliferation, Peroxisome Proliferation Activated Receptor Gamma, CAAT/enhancer Binding Protein Mrna and Protein Expression in 3T3-L1 Pre-Adipocytes].

Berberine attenuates obesity‐induced insulin resistance by inhibiting miR‐27a secretion

Circulating Mir-143-3p Inhibition Protects Against Insulin Resistance in Metabolic Syndrome Via Targeting of the Insulin-Like Growth Factor 2 Receptor.

Curcumin Modulates Mir‐19/pten/akt/p53 Axis to Suppress Bisphenol A‐induced MCF‐7 Breast Cancer Cell Proliferation

Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease

Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice

Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation

Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats

MiR-27a promotes insulin resistance and mediates glucose metabolism by targeting PPAR-γ-mediated PI3K/AKT signaling

Berberine Ameliorates High-fat-induced Insulin Resistance in HepG2 Cells by Modulating PPARs Signaling Pathway

Characterizing and identifying of miRNAs involved in berberine modulating glucose metabolism of Megalobrama amblycephala

Berberine downregulates microRNA24 in rat cardiomyocyte and its possible mechanism

Berberine Potentiates Insulin Secretion and Prevents β-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway

Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism

Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway

Mir-199A-3p Regulates Brown Adipocyte Differentiation Through Mtor Signaling Pathway

Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells